Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi

被引：67

作者：

Merli, Francesco ^{[1
]}

Luminari, Stefano ^{[2
]}

Rossi, Giuseppe ^{[3
]}

Mammi, Caterina ^{[1
]}

Marcheselli, Luigi ^{[2
]}

Ferrari, Angela ^{[1
]}

Spina, Michele ^{[4
]}

Tucci, Alessandra ^{[3
]}

Stelitano, Caterina ^{[5
]}

Capodanno, Isabella ^{[1
]}

Fragasso, Alberto ^{[6
]}

Baldini, Luca ^{[7
]}

Bottelli, Chiara ^{[3
]}

Montechiarello, Elisa ^{[5
]}

Fogazzi, Stefano ^{[3
]}

Lamorgese, Cinzia ^{[3
]}

Cavalli, Lara ^{[3
]}

Federico, Massimo ^{[2
]}

机构：

[1] Arcispedale Santa Maria Nuova, Hematol Unit, Ist Ricovero & Cura Carattere Sci, I-42123 Reggio Emilia, Italy

[2] Univ Modena & Reggio Emilia, Dept Hematol & Oncol, Modena, Italy

[3] Spedali Civil Brescia, Div Hematol, I-25125 Brescia, Italy

[4] Natl Canc Inst, Div Med Oncol A, Aviano, Italy

[5] Azienda Osped Bianchi Melacrino Morelli, Dept Hematol, Reggio Di Calabria, Italy

[6] Osped Madonna Grazie, Hematol Unit, Dept Internal Med, Matera, Italy

[7] Univ Milan, Ca Granda Hosp Maggiore Policlin, IRCCS Fdn, Hematol Unit 1, Milan, Italy

来源：

LEUKEMIA & LYMPHOMA | 2014年 / 55卷 / 01期

关键词：

Diffuse large B-cell lymphoma (DLBCL); elderly patients; frail patients; Comprehensive Geriatric Assessment (CGA); chemotherapy; rituximab; NON-HODGKINS-LYMPHOMA; TRIAL; CHEMOTHERAPY; RITUXIMAB; DOXORUBICIN; CANCER; CHOP; MANAGEMENT; RICOVER-60;

D O I：

10.3109/10428194.2013.788176

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In 2003 the Fondazione Italiana Linfomi (FIL) started a clinical research program for investigating initial treatment of frail elderly patients with diffuse large B-cell lymphoma (DLBCL) identified by Comprehensive Geriatric Assessment (CGA). From 2003 to 2006, 334 elderly patients underwent CGA assessment, and 99 patients were classified as frail. Frail patients had a median age of 78 years, stage III-IV disease in 62% and age-adjusted International Prognostic Index (aaIPI) of 2-3 in 53%. Treatment consisted of several different regimens according to physician discretion. After a median follow-up of 36 months, 5-year overall survival (OS) was 28%. In multivariate analysis, aaIPI 2-3 (p=0.005) and the presence of respiratory comorbidity (p=0.044) were the only factors that showed independent correlation with OS. Frail patients had a poorer outcome compared with fit patients also if they were treated with rituximab-containing combination chemotherapy (hazard ratio 2.37, 95% confidence interval 1.48-3.78; p<0.001). CGA is a valid tool to prospectively identify frail subjects among elderly patients with DLBCL.

引用

页码：38 / 43

页数：6

共 50 条

[41] LATE TOXICITIES AND LONG-TERM MONITORING IN CLASSICAL HODGKIN LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA SURVIVORS: A SERIES OF SYSTEMATIC REVIEWS OF THE FONDAZIONE ITALIANA LINFOMI
Minoia, C.
Gerardi, C.
Allocati, E.
De Sanctis, V.
Franceschetti, S.
Viviani, S.
Annunziata, M. A.
Bari, A.
Skrypets, T.
Oliva, S.
Puzzovivo, A.
Di Molfetta, S.
Caccavari, V.
Di Russo, A.
Loseto, G.
Daniele, A.
Nassi, L.
Gini, G.
Guarini, A.
HAEMATOLOGICA, 2021, 106 (10) : 170 - 170
[42] Late Toxicities and Long-Term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Series of Systematic Reviews of the Fondazione Italiana Linfomi
Minoia, Carla
Gerardi, Chiara
Allocati, Eleonora
De Sanctis, Vitaliana
Franceschetti, Silvia
Viviani, Simonetta
Annunziata, Maria Antonietta
Bari, Alessia
Skrypeta, Tetiana
Oliva, Stefano
Puzzovivo, Agata
Di Molfetta, Sergio
Caccavari, Valentina
Di Russo, Anna
Loseto, Giacomo
Daniele, Antonella
Nassi, Luca
Gini, Guido
Guarini, Attilio
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S374 - S375
[43] LENALIDOMIDE PLUS RITUXIMAB-CHOP21 IN ELDERLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA IS PROMISING: LONG TERM RESULTS OF THE PHASE II REAL07 STUDY OF THE FONDAZIONE ITALIANA LINFOMI (FIL)
Chiappella, A.
Castellino, A.
Franceschetti, S.
Carella, A.
Baldi, I.
Zanni, M.
Liberati, A.
Spina, M.
Tucci, A.
Pavone, V.
Molinari, A.
Zinzani, P.
Salvi, F.
Fattori, P.
Zaccaria, A.
Botto, B.
Congiu, A.
Ladetto, M.
Dreyling, M.
Gaidano, G.
Inghirami, G.
Rossi, G.
Vitolo, U.
HAEMATOLOGICA, 2013, 98 : 356 - 356
[44] Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi
Chiappella, Annalisa
Franceschetti, Silvia
Castellino, Alessia
Carella, Angelo Michele
Baldi, Ileana
Zanni, Manuela
Liberati, Anna Marina
Spina, Michele
Tucci, Alessandra
Pavone, Vincenzo
Molinari, Anna Lia
Zinzani, Pier Luigi
Salvi, Flavia
Gaudiano, Marcello
Fattori, Pier Paolo
Zaccaria, Alfonso
Botto, Barbara
Congiu, Angela
Ciccone, Giovannino
Ladetto, Marco
Dreyling, Martin
Gaidano, Gianluca
Inghirami, Giorgio
Rossi, Giuseppe
Vitolo, Umberto
BLOOD, 2013, 122 (21)
[45] Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma (vol 130, pg 2180, 2017)
Lin, R. J.
Behera, M.
Diefenbach, C. S.
Flowers, C. R.
BLOOD, 2018, 131 (09) : 1037 - 1037
[46] Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for "unfit' patients classified by comprehensive geriatric assessment
Yoshida, Masahiro
Nakao, Takafumi
Horiuchi, Mirei
Ueda, Hideya
Hagihara, Kiyoyuki
Kanashima, Hiroshi
Inoue, Takeshi
Sakamoto, Erina
Hirai, Manabu
Koh, Hideo
Nakane, Takahiko
Hino, Masayuki
Yamane, Takahisa
EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 96 (04) : 409 - 416
[47] Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi
Luminari, Stefano
Viel, Elda
Ferreri, Andres Jose Maria
Zaja, Francesco
Chimienti, Emanuela
Musuraca, Gerardo
Tucci, Alessandra
Balzarotti, Monica
Tani, Monica
Salvi, Francesca
Pesce, Emanuela A.
Ferrari, Angela
Liberati, Anna M.
Spadea, Antonio
Marino, Dario
Bruno-Ventre, Maria
Volpetti, Stefano
Bottelli, Chiara
Ravaioli, Elena
Merli, Francesco
Spina, Michele
HEMATOLOGICAL ONCOLOGY, 2018, 36 (01) : 68 - 75
[48] Late Endocrine and Metabolic Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi
Di Molfetta, Sergio
Daniele, Antonella
Gerardi, Chiara
Allocati, Eleonora
Minoia, Carla
Loseto, Giacomo
Giorgino, Francesco
Guarini, Attilio
De Sanctis, Vitaliana
CANCERS, 2022, 14 (06)
[49] RITUXIMAB, BENDAMUSTINE AND CYTARABINE AS INDUCTION THERAPY IN ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA: A PHASE 2 STUDY FROM THE FONDAZIONE ITALIANA LINFOMI
Visco, C.
Chiappella, A.
Franceschetti, S.
Patti, C.
Ferrero, S.
Barbero, D.
Evangelista, A.
Spina, M.
Molinari, A.
Rigacci, L.
Tani, M.
Di Rocco, A.
Pinotti, G.
Fabbri, A.
Zambello, R.
Finotto, S.
Gotti, M.
Carella, A. M.
Salvi, F.
Pileri, S. A.
Ladetto, M.
Zaja, F.
Gaidano, G.
Vitolo, U.
Rodeghiero, F.
HAEMATOLOGICA, 2015, 100 : 4 - 4
[50] Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi
Arcaini, L.
Vallisa, D.
Rattotti, S.
Ferretti, V. V.
Ferreri, A. J. M.
Bernuzzi, P.
Merli, M.
Varettoni, M.
Chiappella, A.
Ambrosetti, A.
Tucci, A.
Rusconi, C.
Visco, C.
Spina, M.
Cabras, G.
Luminari, S.
Tucci, M.
Musto, P.
Ladetto, M.
Merli, F.
Stelitano, C.
d'Arco, A.
Rigacci, L.
Levis, A.
Rossi, D.
Spedini, P.
Mancuso, S.
Marino, D.
Bruno, R.
Baldini, L.
Pulsoni, A.
ANNALS OF ONCOLOGY, 2014, 25 (07) : 1404 - 1410

← 1 2 3 4 5 →